# An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051 (Vesleteplirsen)

> **NCT03675126** · PHASE1,PHASE2 · TERMINATED · sponsor: **Sarepta Therapeutics, Inc.** · enrollment: 15 (actual)

## Conditions studied

- Muscular Dystrophy, Duchenne

## Interventions

- **DRUG:** SRP-5051

## Key facts

- **NCT ID:** NCT03675126
- **Lead sponsor:** Sarepta Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-12-19
- **Primary completion:** 2021-08-25
- **Final completion:** 2021-08-25
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** The sponsor has decided to integrate 5051-102 into 5051-201. Participants from 5051-102 will be eligible to enroll in 5051-201 Part B.
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03675126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03675126, "An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051 (Vesleteplirsen)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03675126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*